Neogenomics (NEO) Equity Ratio (2010 - 2026)

Neogenomics (NEO) has reported Equity Ratio for 17 consecutive years, with 0.62 the latest figure, recorded in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.62, up 10.96% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.62 (up 10.96% YoY), and the FY2025 annual result was 0.62, up 11.68% from the prior year.
• Equity Ratio was 0.62 for Q1 2026 at Neogenomics, roughly flat from 0.62 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.62 in Q1 2026 and troughed at 0.55 in Q4 2024.
• Average Equity Ratio over 5 years is 0.58, with a median of 0.57 recorded in 2023.
• Year-over-year, Equity Ratio decreased 3.85% in 2022 and rose 11.68% in 2025.
• Over 5 years, Equity Ratio stood at 0.57 in 2022, then fell by 2.36% to 0.56 in 2023, then decreased by 1.64% to 0.55 in 2024, then increased by 11.68% to 0.62 in 2025, then gained by 0.05% to 0.62 in 2026.
• Per Business Quant data, the three most recent Equity Ratio figures were 0.62 in Q1 2026, 0.62 in Q4 2025, and 0.61 in Q3 2025.